CVKD: Phase 2 HIT Results Show Encouraging Reduction in Thrombotic Events

About this update from Cadrenal Therapeutics, Inc.

[{"type":"text","content":"By David Bautz, PhD","length":19,"tagName":"p"},{"type":"text","content":"NASDAQ:CVKD","length":11,"tagName":"p"},{"type":"text","content":"READ THE FULL CVKD RESEARCH REPORT","length":34,"tagName":"p"},{"type":"text","content":"Business Update","length":15,"tagName":"p"},{"type":"text","content":"Encouraging Results from Phase 2 HIT Trial","length":42,"tagName":"p"},{"type":"text","content":"On February 24, 2026, Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced encouraging results from the Phase 2 trial of CAD-1005 (formerly CAD-1005) in heparin-induced thrombocytopenia (HIT). The results showed a meaningful reduction in thrombotic events despite not meeting the study’s primary endpoint of platelet count recovery. While platelet recovery did not differ between treatment groups, thrombotic events occurred in 50% of CAD-1005-treated patients compared with >75% in placebo-treated patients, which represents a >25% absolute reduction. Although the study was not powered for statistical significance, the signal is clinically compelling in a condition with a high morbidity and mortality, and no approved therapies specifically targeting the immune mechanism underlying HIT.","length":796,"tagName":"p"},{"type":"text","content":"The randomized, placebo controlled Phase 2 study evaluated CAD-1005, a selective inhibitor of 12-lipoxygenase (12-LOX) in patients with suspected HIT receiving standard anticoagulant therapy (argatroban or bivalirudin). The trial was initiated by Veralox Therapeutics, which selected platelet count recovery rate as the primary endpoint. The strategic intent of that design was to determine whether platelet count recovery could serve as a surrogate endpoint for clinical outcomes in a future registrational study. In other words, the Phase 2 trial was structured not only to evaluate efficacy, but to test whether platelet count recovery could reliably predict reductions in thrombotic events. Following the acquisition by Cadrenal, the study concluded with 24 randomized patients, 17 of whom had centrally confirmed HIT.","length":822,"tagName":"p"},{"type":"text","content":"The study did not demonstrate a difference in platelet count recovery between treatment arms. In addition, thrombotic events continued to occur even after platelet count recovery in both arms. This indicates that platelet count recovery may not...

More updates from Cadrenal Therapeutics, Inc.